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Objective: This study is to examine the effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-
14 taken orally before bedtime on Group B Streptococcus (GBS)-positive pregnant women with respect to
becoming GBS negative.
Materials and Methods: In total, 110 pregnant women at 35e37 weeks of gestation who were diagnosed
by GBS culture as being GBS positive for both vaginal and rectal GBS colonization were randomly
assigned to be orally treated with two placebo capsules or two probiotic capsules (containing
L. rhamnosus GR-1 and L. reuteri RC-14) before bedtime until delivery. All women were tested for vaginal
and rectal GBS colonization again by GBS culture on admission for delivery.
Results: Of the 110 participants, 99 completed the study (49 in the probiotic group and 50 in the placebo
group). The GBS colonization results changed from positive to negative in 21 women in the probiotic
group (42.9%) and in nine women in the placebo group (18.0%) during this period (Chi-square p¼ 0.007).
Conclusion: Oral probiotic containing L. rhamnosus GR-1 and L. reuteri RC-14 could reduce the vaginal and
rectal GBS colonization rate in pregnant women.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Group B Streptococcus (GBS) is an encapsulated Gram-positive
coccus that colonizes the gastrointestinal and genital tracts of
15e40% of pregnant women [1]. Although GBS colonization
usually remains asymptomatic in these women, vertical trans-
mission may occur when GBS ascends from the vagina to the
amniotic ﬂuid after the onset of labor or rupture of the mem-
branes. In some cases, transmission can take place with intact
membranes [2,3]. During the past 2 decades, GBS has been
considered to be a leading cause of primary neonatal sepsis,
pneumonia, and meningitis in the 1st week of life, which is
known as early-onset GBS infection [4]. Intrapartum parenteral
antibiotic prophylaxis for women with a positive GBS culture atand Gynecology, China Med-
ichung 404, Taiwan, ROC.
iu).
bstetrics & Gynecology. Published b35e37 weeks of gestation is recommended by the Centers for
Disease Control and Prevention (CDC). According to the 2010 CDC
guidelines, a minimum of 4 hours of intrapartum antibiotic pro-
phylaxis prior to delivery is recommended to prevent early-onset
GBS infection because therapeutic drug level may not be achieved
with < 4 hours of treatment [5]. Preliminary studies and data
from a large health maintenance organization showed that
40e50% of GBS-colonized multiparous women are not able to
receive antibiotics at least 4 hours before delivery due to the
rapidity of their labor [6]. Newborns from GBS positive women
with inadequate intrapartum antibiotic prophylaxis are deemed at
risk. Low-risk infants are recommended to undergo 48 hours of
observation. High-risk infants should additionally undergo blood
cultures and a complete blood count [5]. GBS disease is not easily
resolved by antibiotic treatment of the pathogen. Thus, such
traditional approaches need to be re-evaluated.
Lactobacilli are the dominant bacteria of the vaginal ﬂora. They
possess antimicrobial properties that regulate other urogenitaly Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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the vagina include modulation of host immunity, alteration of the
microenvironment to be less receptive to pathogens (i.e. the pro-
duction of lactic acid, bacteriocin, biosurfactants, hydrogen
peroxide, and signaling compounds), and dislodging pathogen
bioﬁlms [7]. Using probiotic during pregnancy has an excellent
safety record [8]. Taking oral probiotics containing lactobacilli
daily has been shown to maintain normal lactobacilli vaginal ﬂora
[9]. Reid et al [10] showed that Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14 are antagonistic to the growth and
adhesion of various intestinal and urogenital pathogens, including
GBS, Gardnerella vaginalis, and uropathogenic Escherichia coli. A
study by Altoparlak et al [11] showed a negative correlation be-
tween the colonization rate of vaginal lactobacilli and GBS in
pregnant women. The lactobacilli colonization rate was 21.3% in
the GBS positive group, and 47.6% in the GBS negative group [11].
These results suggest that lactobacilli play a role in preventing
vaginal colonization by GBS. The study of Velraeds et al [12] has
also shown that certain lactobacilli can inhibit the growth and
adhesion of streptococci in vitro. However, their ability to do so
in vivo needs further testing.
Most research to date has focused on the potential of probiotics
to prevent bacterial vaginosis and preterm labor. The effectiveness
of probiotics as a surrogate or adjunctive therapy for intrapartum
antibiotic prophylaxis in GBS colonized pregnant women has not
been evaluated. To our knowledge, the present study is the ﬁrst to
investigate the role of probiotics in preventing and treating vaginal
colonization by GBS in pregnant women. The purpose of this study
was to examine whether oral Lactobacillus-containing probiotics
can reduce the vaginal and rectal GBS colonization rate in GBS
positive pregnant. Through the results of our study, we try to
investigate the role of probiotics in preventing unnecessary tests,
admission, and antibiotic treatments in newborns from GBS-
positive mothers. We hope our study will have some impact on
GBS sepsis protocols.
Materials and methods
This study was a prospective, double-blind randomized clinical
trial that was performed in the Obstetric Department of the China
Medical UniversityHospital, Taichung, Taiwan fromMarch 1, 2011 to
December 30, 2011. This research study was approved by the China
Medical University Hospital Institutional Review Board (DMR99-
IRB-309) and registered in the Clinical Trials.gov Protocol Registra-
tion and Results System (registration number NCT01577108).
Written informed consent was obtained from each participant.
The inclusion criteria of our study were pregnant women,
singleton pregnancy, with a positive GBS screening culture at
35e37 weeks of gestation. They agreed, throughout the trial
period, to abstain from the use of any systemic or intravaginal
antibiotic, antifungal agents, or any other intravaginal product
(e.g., contraceptive creams, lubricants, and douches). The exclu-
sion criteria included multiple gestations, pregnant women with
impaired immunity, diabetes, or any other kind of signiﬁcant
disease or acute illness that could complicate the evaluation of the
results. Pregnant women who received vaginal or systemic anti-
biotics and antifungal therapy within 2 weeks of the screening
visit were also excluded.
Vaginal and rectal GBS screening cultures by swabbing both the
lower vagina and rectum (through the anal sphincter) were per-
formed for all pregnant women at 35e37 weeks of gestation in our
outpatient department. The specimens were transported to labo-
ratory as soon as possible and inoculated into the Lim broth.
Women with vaginal and rectal GBS colonization were invited to
participate in our study. Informed consent was obtained from eachparticipant. The trial patients were doubled-blind computerized
randomized by the hospital pharmacy. Each woman was assigned
a number. Identical looking probiotic and placebo capsules were
prepared and distributed in numbered containers by the phar-
macy. The patients were provided two capsules of probiotics or
placebos to be taken once daily at bedtime until delivery. The
probiotic capsules contained dried viable L. rhamnosus GR-1 and
L. reuteri RC-14, and each capsule contained 1 109 viable cells of
both strains. The L. rhamnosus GR-1 and L. reuteri RC-14 strains
were encapsulated in gelatin capsules, which were produced by
Chr. Hansen (Horsholm, Denmark) using good manufacturing
practices (U-relax). The placebo capsules contained the same
composition (dextrose anhydrate, potato starch, microcrystalline
cellulose, and magnesium stearate, gelatin, and titanium dioxide)
except for the L. rhamnosus GR-1 and L. reuteri RC-14 strains.
Vaginal and rectal GBS cultures were repeated for all participants
at the time of admission for delivery. All the participants were
treated according to the CDC's 2010 guidelines on GBS (GBS-pos-
itive mothers as assessed by culture at 35e37 weeks of gestation
should receive at least 4 hours of intrapartum antibiotic prophy-
laxis) on admission for labor.
The primary outcome was the absence of vaginal and rectal GBS
colonization in pregnant women who presented as GBS positive at
35e37 weeks of gestation after probiotics or placebo treatment.
The secondary measures were the relationship between parity and
newborn transfer units, and the cause of admittance to the neonatal
unit. The Wilcoxon rank-sum test and Chi-square test were used to
test for signiﬁcant differences between the two groups in terms of
maternal age, maternal weight, education level, parity, gestational
week of delivery, duration of drug taking, neonatal birth weight,
newborn transfer units, and Apgar scores. The Chi-square test was
also used to evaluate the difference in the primary outcome be-
tween probiotics and placebo groups, the cause of admission to the
neonatal unit, and the relationship between parity and newborn
transfer units. Assuming GBS culture to become negative in > 40%
of the participants in the study group and not > 15% in the placebo
group, a sample size of 50 women per group was considered suf-
ﬁcient to reach 80% statistical power. All statistical analyses were
calculated using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). A p
value < 0.05 was considered to be statistically signiﬁcant.
Results
The study was conducted in our hospital from March 2011 to
December 2011. During the trial period, 1210 women, at 35e37
weeks of gestation, underwent vaginal and rectal GBS screening
cultures in our outpatient department; 219 women had positive
culture results. The GBS colonization rate was 18.1%. Therewere 110
pregnant women enrolled in the study. Overall, 99 participants
completed the study. Three participants, two in the study group
and one in the control group, dropped out of the study because of
failure to undergo the GBS culture before delivery. Eight partici-
pants, four in the study group and four in the control group,
withdrew from the study due to personal reason. A CONSORT ﬂow
diagram depicting information about the number of participants at
the different stages of the trial is shown in Figure 1.
The demographic and clinical characteristics of the two groups
are shown in Table 1. There were no signiﬁcant differences between
the two groups in terms of the following factors: maternal age,
maternal weight, education level, parity, gestational week of de-
livery, duration of drug taking, neonatal birth weight, newborn
transfer units, and Apgar score. There were no adverse treatment
effects in terms of nausea, vomiting, diarrhea, abdominal pain, skin
rash, or systemic infections after taking the capsules in any of the
participants during the trial. In total, 24 neonates were transferred
Randomized for the study
(n = 110)
Received probiocs (n = 55) Received placebo (n = 55)
Dropped out the study (n = 6)
2 failure to undergo the GBS 
culture before delivery
4 due to personal reason
Dropped out the study (n = 5)
1 failure to undergo the GBS 
culture before delivery
4 due to personal reason
Analyzed for primary outcome 
(n = 49)
Nulliparous (n = 32)
Mulparous (n = 17)
Analyzed for primary outcome 
(n = 50)
Nulliparous (n = 34)
Mulparous (n = 16)
GBS culture negave (n = 21)
Nulliparous (n = 15)
Mulparous (n = 6)
GBS culture negave (n = 9)
Nulliparous (n = 7)
Mulparous (n = 2)
Assessed for eligibility
(n = 219)
Excluded (n = 109)
Not meeng inclusion criteria
(n = 37)
Declined to parcipate (n = 72)
Figure 1. Flow diagram showing the number (n) of participants at different stages of
the trial.
Table 1
Characteristics of the women and newborn in the study.
Probiotic (n¼ 49) Placebo (n¼ 50) p
Maternal age (y)a 32.0± 4.0 32.0± 3.7 0.33
Maternal weight (kg)a 67.0± 4.7 68.0± 5.1 0.59
Gestational age (wk)a 39± 0.9 39± 1.1 0.19
Education levelb 0.11
Below college 8 2
College 41 48
Parityb 0.99
Nulliparous 32 34
Multiparous  1 17 16
Duration of takinga (d) 21.2± 5.5 19.6± 4.8 0.76
Weight of newborna (g) 3123± 398 3230± 358 0.07
Newborn transfer unitsb 0.62
Sick baby room 10 14
Baby room 38 34
Intensive care unit 1 2
Apgar score < 7b > 0.999
1 min 0 0
5 min 0 0
Data are expressed as mean± standard deviation or n.
a Wilcoxon rank-sum test.
b Chi-square test.
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and 14 from multiparous mothers, had inadequate antibiotic
treatment prior to delivery (< 4 hours before delivery). One
neonate had hydronephrosis. One had intrapartum maternal fever.
The remaining two had dyspnea after delivery. Results by the Chi-square test showed that the main cause of admission to sick baby
room was due to inadequate antibiotic treatment (p¼ 0.001).
Among our participants, 33 were multiparous and 66 nulliparous.
Fifteen of the neonates from multiparous (45.5%), but only nine
neonates from nulliparous women (13.6%) were transferred to the
sick baby room. The Chi-square test showed a strong relationship
between parity and the transfer rate to the sick baby room
(p< 0.001). At the time of labor, nine of 50 participants in the
placebo group (18.0%) and 21 of 49 participants in the probiotic
group (42.9%) became GBS negative. The Chi-square statistical
analysis showed a p value of 0.007, which suggests a signiﬁcant
difference in the negative GBS culture rate between the two groups.
Discussion
In our trial, 42.9% of the participants in the study group but only
18.0% in the placebo group achieved a negative GBS culture at the
time of delivery. The results demonstrated that oral probiotic
L. rhamnosus GR-1 and L. reuteri RC-14 could reduce vaginal and
rectal GBS colonization in pregnant women. To our knowledge, this
was the ﬁrst clinical trial to use probiotics as a regimen for reducing
the vaginal and rectal GBS colonization in pregnant women. A
previous study showed that certain lactobacilli can inhibit the
growth and adhesion of streptococci in vitro [12]. However, their
ability in vivo was not tested. According to a study by Altoparlak
et al [11], the Lactobacillus colonization rate was lower when
combined with GBS colonization during pregnancy. A study by
Kubota et al [13] also demonstrated that GBS inhibited Lactobacillus
in vitro. These ﬁndings supported the idea that increasing the
amount of Lactobacillus could reduce GBS colonization. However,
the actual mechanism of probiotics in reducing GBS colonization
was not investigated in our trial.
Even with the most valiant efforts, 40e50% of multiparous
pregnant women colonized with GBS still have < 4 hours before
delivery to be treated with preventive antibiotics [6]. In our study,
24 neonates were transferred to the sick baby room. Among these
neonates, 45.5% came from multiparous women, but only 13.6%
from nulliparous women. Owing to the rapidity of labor, intra-
partum antibiotic prophylaxis to prevent early-onset GBS infection
in multiparous patients is limited and ineffective. Thus, the current
GBS prevention policy needs to be re-evaluated. In the absence of a
plan to counteract the rapidity of labor in GBS-colonized pregnant
women, particularly in multiparous patients, reducing the prenatal
GBS colonization rate should be the touchstone in early-onset GBS
disease prevention.
Reducing GBS colonization in pregnant women is the golden
standard of the prevention of early-onset GBS disease in newborns.
Our study results showed that nearly 43% of the GBS-positive
pregnant women achieved negative GBS culture results after tak-
ing probiotics for ~3 weeks. A reduction in GBS colonization posi-
tivity at 35e37 weeks of gestation can reduce the early-onset GBS
infection rate and the antibiotic usage during labor. Thus, probiotics
have the potential to decrease the risk of early-onset GBS disease
and the rate of antibiotic use during labor just by restoring normal
vaginal ﬂora and acidity without systemic effects. During preg-
nancy, treatment that can achieve the same goals but less invasive
or with less adverse effects should be chosen. We propose that
those in the high-risk group of GBS colonization during pregnancy
(e.g., healthcare workers, black women, women with a high body
mass index, and women with previous GBS infection or coloniza-
tion) [14] and those who are multiparous should start oral pro-
biotics from the beginning of the third trimester for the purpose of
reducing prenatal GBS colonization. GBS screening and intrapartum
management of these women should follow the CDC guidelines on
GBS.
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small. All patients came from a single hospital and resided in the
city of Taichung, Taiwan. Therefore, our ﬁndings cannot be
generalized across different regions and races. Our study was not
set up for long-term observation of neonatal outcomes. There was
no cost-effectiveness analysis in our study. We also did not
discuss the mechanisms of probiotics due to a lack of under-
standing on this aspect. In addition, our participants took pro-
biotics for an average of 20 days. This might not be long enough
for Lactobacillus to repopulate inside the vagina, displace patho-
gens, modulate host immunity, and alter the microenvironment
of the vagina. Furthermore, our study lacked the information of
the socioeconomic status, dietary habits, and the use of nutri-
tional supplement of the participants. Therefore, the effectiveness
of probiotic treatment in reducing the rate of GBS colonization
remains speculative. In future, more research will be done on this
subject to address our study limitations and corroborate our
ﬁndings.
In conclusion, our study demonstrated that oral probiotics
containing L. rhamnosus GR-1 and L. reuteri RC-14 could reduce the
vaginal and rectal GBS colonization in pregnant women. We pro-
pose that oral probiotics should be administered early in preg-
nancy to reduce GBS colonization at 35e37 weeks of gestation.
This could reduce early-onset GBS infection and the need for
antibiotic treatment during labor. Moreover, it might help to
overcome inadequate antibiotic treatment during labor in
multiparous women and lead to a reduction of admission rate to
the neonatal unit.Conﬂicts of interest
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